Hoang V. Le

2023–Present:  Program Officer at the National Institute on Drug Abuse

2016–2023:  Assistant Professor of Medicinal Chemistry, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi

2016–2023:  Research Assistant Professor, Research Institute of Pharmaceutical Sciences
School of Pharmacy, University of Mississippi

​2020–2023:  Member, UMMC Cancer Center and Research Institute

2019–2021:  Graduate Program Coordinator, Medicinal Chemistry Division, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi

2018–2019:  Visiting Scientist, St. Jude Children's Research Hospital

Postdoctoral Researcher, Northwestern University (2013 - 2016). Advisor: Richard Silverman

Ph.D., Cornell University, 2013. Advisor: Bruce Ganem

B.S., University of California, Berkeley, 2008. Advisor: Kenneth Raymond

2021:  P2 Teaching Team of the Year Award (Team Member), UM School of Pharmacy

2020:  P1 Teaching Team of the Year Award (Team Leader), UM School of Pharmacy

2018:  New Investigator Award, American Association of Colleges of Pharmacy (AACP)

​2010–2012:   NIH Chemistry/Biology Interface Training Grant Award

Co-inventor of OV329,  a Phase 1 drug candidate to treat seizures associated with tuberous sclerosis complex and infantile spasms, licensed to Ovid Therapeutics (2016–Present).

10/2011­–11/2011:  ​Avila Therapeutics, Inc. (now part of Bristol Myers Squibb)

2023:  Guest Editor, "Current Research Methods in Natural Product-Inspired Drug Discovery",  Journal of Visualized Experiments (JoVE)

2021:  Topic Editor, "Targeting Cancer Metabolic Reprogramming for Cancer Therapy", Frontiers in Drug Discovery 

2021–Present:  Associate Editor, Frontiers in Drug Discovery 

2023:  Reviewer, Austrian Science Fund (FWF)

2022–2023:  Reviewer, NSF Graduate Research Fellowships Program (GRFP)

2021–2022:  Reviewer, NSF Graduate Research Fellowships Program (GRFP)

2021:  Reviewer, NSF SBIR/STTR program

2020–2021:  Reviewer, NSF Graduate Research Fellowships Program (GRFP)

​2019–2020:  Reviewer, NSF Graduate Research Fellowships Program (GRFP)

2018–2019:  Reviewer, NSF Graduate Research Fellowships Program (GRFP)

2018:  Reviewer, Innovational Research Incentive Scheme – Veni Programme

2017:  Reviewer, NIH Macromolecular Structure and Function A Study Section

2017:  NIH Early Career Reviewer Program 

2022–2023:  Chair, American Chemical Society Ole Miss Local Section

2022–2023:  Member, AACP Chemistry Section Resolutions Committee 

2022:  ACS Leadership Institute

2021–2022:  Member, AACP Chemistry Section Awards Committee 

2021–2022:  Chair-Elect, American Chemical Society Ole Miss Local Section

2021–2022:  Vice-Chair, Research and Graduate Affairs Committee, School of Pharmacy, University of Mississippi 

2021–2022:  Member, UM Mentoring Working Group 

2021–2023:  Member, UM Graduate School's Graduate Student Mental Health and Well-being Advisory Board

2020–2021:  Member, AACP Chemistry Section Awards Committee

2018–2021:  Secretary (elected in 2018; re-elected in 2019 and 2020), American Chemical Society Ole Miss Local Section

​2020–2021:  Vice-Chair, Research and Graduate Affairs Committee, School of Pharmacy, University of Mississippi

2019–2023:  Faculty Advisor, Ole Miss Vietnamese American Student Association (Ole VASA) 

2019–2020:  Member, AACP New Investigator Awards Review Committee

2019–2020:  Vice-Chair, Research and Graduate Affairs Committee, School of Pharmacy, University of Mississippi

2017–2021:  Founder and Director, Science, Technology, Engineering, and Math Summer Research Experience for Undergraduates (STEMS REU) Program, University of Mississippi

2016–2019:  Member, Research and Graduate Affairs Committee, School of Pharmacy, University of Mississippi 

2022:  Center for the Improvement of Mentored Experiences in Research (CIMER)’s Research Mentoring Training

2022:  Judge (oral and poster presentations), MALTO Medicinal Chemistry and Pharmacognosy Meeting-in-Miniature

2022:  Poster Abstract Reviewer, Pharmacy Education: The 2022 AACP Annual Meeting

2022:  National Research Mentoring Network (NRMN)'s Grant Writing Coaching Program

2021:  Poster Abstract Reviewer, Virtual Pharmacy Education: The 2021 AACP Annual Meeting

2021:  Judge, Regional Science Fair for Elementary Schools

2018:  NIGMS Mentoring Workshop for New Faculty in Organic and Biological Chemistry

2018:  NSF Chemistry Early Career Investigator Workshop

2018:  Judge (oral and poster presentations), MALTO Medicinal Chemistry and Pharmacognosy Meeting-in-Miniature

2018–Present:  Member, Experimental Therapeutics Group, UMMC Cancer Center and Research Institute

2018:  Poster Judge, Southeastern Undergraduate Research Conference (SURC)

2017–2023:  Interviewer, SOP Early Entry/Regular Entry Pharmacy Program

2017:  Judge (oral and poster presentations), MALTO Medicinal Chemistry and Pharmacognosy Meeting-in-Miniature

2015:  NIH Training in Neurotherapeutics Discovery and Development for Academic Scientists 

American Association of Colleges of Pharmacy

American Chemical Society (Divisions of Medicinal Chemistry and Organic Chemistry)

The Rho Chi Society (the Academic Honor Society in Pharmacy)

University of Mississippi (n = 2)

14) Le, H. V.; Paris, J. R.;  Mahdi, F.;  Khan, M. I. H. International/U.S. Patent Application PCT/US2022/075220 (filed August 19, 2022).  Allopregnanolone analogues for HIV viremia and neurotoxicity protection.

13) Le, H. V.; Hossain, M. I. U.S. Patent Application 17,597,550 (filed January 11, 2022). L-γ-methyleneglutamine compounds and methods of use.

Northwestern University (n = 12)

12) Silverman, R. B.; Takaya, K.; Le, H. V.; Juncosa, J. I. India Patent IN 372532 (July 23, 2021). (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction, and hepatocellular carcinoma.

11) Silverman, R. B.; Takaya, K.; Le, H. V.; Juncosa, J. I. Australia Patent AU 2016334396 (July 22, 2021). (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction, and hepatocellular carcinoma.

10) Silverman, R. B.; Juncosa, J.; Le, H. V.; Takaya, K. Israel Patent, IL 258516 (April 1, 2021). (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, a highly potent GABA aminotransferase inactivator for the treatment of epilepsy, addiction, and hepatocellular carcinoma. 

9) Silverman, R. B.; Juncosa, J.; Le, H. V.; Takaya, K. Japan Patent, JP 6841821 (February 22, 2021). (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the yreatment of epilepsy, addiction, and hepatocellular carcinoma. 

8) Silverman, R. B.; Juncosa, J.; Le, H. V.; Takaya, K. China Patent, ZL 2016800590699 (February 12, 2021). (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, a highly potent GABA aminotransferase inactivator for the treatment of epilepsy, addiction, and hepatocellular carcinoma. 

7) Silverman, R. B.; Le, H. V.; Hawker, D. D. U.S. Patent 10,800,753 B2 (October 13, 2020). Tetrahydrothiophene-based GABA aminotransferase inactivators and analogs thereof for treating neurological disorders.

6) Silverman, R. B.; Le, H. V.; McLeod, R. L.; Hawker, D. D. U.S. Patent 10,632,088 B2 (April 28, 2020). Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria. 

5) Juncosa, J.; Le, H. V.; Silverman, R. B.; Takaya, K., Columbia Patent Certificado Numero 37025 (April 17, 2020). Compuestos derivados del ácido (S)-3-amino-4-(difluorometilenil)ciclopent-1-eno-1-carboxílico como inhibidores de GABA aminotransferase. 

4) Silverman, R. B.; Le, H. V.; Hawker, D. D. U.S. Patent 10,189,807 B2 (January 29, 2019). Tetrahydrothiophene-based GABA aminotransferase inactivators. 

3) Silverman, R. B.; Takaya, K.; Le, H. V.; Juncosa, J. I. U.S. Patent 9,993,449 B2 (June 12, 2018). (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction, and hepatocellular carcinoma.

2) Silverman, R. B.; Hawker, D. D.; Le, H. V. U.S. Patent 9,856,231 B2 (January 2, 2018). Tetrahydrothiophene-based GABA aminotransferase inactivators. 

1) Silverman, R. B.; Takaya, K.; Le, H. V.; Juncosa, J. I. U.S. Patent 9,670,141 B2 (June 6, 2017). (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction, and hepatocellular carcinoma.